AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for F-box only protein 38

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for protein-protein interfaces.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the target alone and in complex with its most relevant partner proteins, followed by ensemble virtual screening that accounts for conformational mobility in free and bound forms. The tentative binding pockets are considered on the protein-protein interface itself and in remote allosteric locations in order to cover the whole spectrum of possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q6PIJ6

UPID:

FBX38_HUMAN

Alternative names:

-

Alternative UPACC:

Q6PIJ6; Q6PK72; Q7Z2U0; Q86VN3; Q9BXY6; Q9H837; Q9HC40

Background:

F-box only protein 38 plays a crucial role in immune regulation by mediating the ubiquitination and proteasomal degradation of PDCD1/PD-1. This process is essential for the regulation of T-cells-mediated immunity and has significant implications for anti-tumor activity. The protein's ability to indirectly stimulate transcription factor KLF7, a key player in neuronal differentiation, further underscores its multifunctional nature.

Therapeutic significance:

Given its pivotal role in modulating T-cell-mediated immunity and its involvement in Neuronopathy, distal hereditary motor, 2D, F-box only protein 38 presents a promising target for therapeutic intervention. Enhancing our understanding of this protein could lead to novel strategies for treating immune-related disorders and certain neurodegenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.